Dance of Proteins – Abraxane celebrates the 10th anniversary of the FDA’s first approval for the treatment of metastatic breast cancer in the United States.
Invented by following our science on stem cells at Abraxis BioScience, Abraxane is the world’s first human protein nanoparticle chemotherapeutic drug approved by the FDA. Ten years later, Abraxane is now approved in three cancer indications, breast cancer, lung cancer and pancreatic cancer in 2013. Continuing this success, promising data has showed improved outcomes for women with triple negative breast cancer, one of the most aggressive cancers with very few treatment options. In this clinical study, 43% of the women in the study were tumor-free. A remarkable improvement for cancer patients in need.